Jyong Biotech Ltd
MENS1.870USD
+0.210+12.65%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
138.82MMarket Cap
LossP/E TTM
More Details of Jyong Biotech Ltd Company
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Jyong Biotech Ltd Info
Ticker SymbolMENS
Company nameJyong Biotech Ltd
IPO dateJun 17, 2025
CEOKuo (Fu-Feng)
Number of employees29
Security typeOrdinary Share
Fiscal year-endJun 17
Address23F-3, No.95, Section 1, Xintai 5th, Xizhi District
CityNEW TAIPEI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryTaiwan
Postal code221
Phone886227325205
Websitehttps://jyongbio.com/
Ticker SymbolMENS
IPO dateJun 17, 2025
CEOKuo (Fu-Feng)
Company Executives of Jyong Biotech Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Alfred Ying
Mr. Alfred Ying
Chief Financial Officer
Chief Financial Officer
4.00K
+4000.00%
Dr. Fenglin Hsu
Dr. Fenglin Hsu
Director and Chief Technology Officer
Director and Chief Technology Officer
3.00K
+3000.00%
Ms. Fu-Feng Kuo
Ms. Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer
Chairwoman of the Board and Chief Executive Officer
--
--
Mr. Hung-Shu Fan
Mr. Hung-Shu Fan
Independent Director
Independent Director
--
--
Mr. Pang-Chief Chi
Mr. Pang-Chief Chi
Independent Director
Independent Director
--
--
Mr. Ming Tsan Hsu
Mr. Ming Tsan Hsu
Independent Director
Independent Director
--
--
Dr. Wanwen (Angela) Su
Dr. Wanwen (Angela) Su
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alfred Ying
Mr. Alfred Ying
Chief Financial Officer
Chief Financial Officer
4.00K
+4000.00%
Dr. Fenglin Hsu
Dr. Fenglin Hsu
Director and Chief Technology Officer
Director and Chief Technology Officer
3.00K
+3000.00%
Ms. Fu-Feng Kuo
Ms. Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer
Chairwoman of the Board and Chief Executive Officer
--
--
Mr. Hung-Shu Fan
Mr. Hung-Shu Fan
Independent Director
Independent Director
--
--
Mr. Pang-Chief Chi
Mr. Pang-Chief Chi
Independent Director
Independent Director
--
--
Mr. Ming Tsan Hsu
Mr. Ming Tsan Hsu
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 5
Updated: Thu, Feb 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perfect Minds Co Ltd
33.34%
Laxton Investments Company Ltd
10.04%
Linkage Gladden Enterprise Ltd
9.03%
Peak Valley International Co., Ltd.
6.71%
Honest Dynasty Ltd
3.08%
Other
37.80%
Shareholders
Shareholders
Proportion
Perfect Minds Co Ltd
33.34%
Laxton Investments Company Ltd
10.04%
Linkage Gladden Enterprise Ltd
9.03%
Peak Valley International Co., Ltd.
6.71%
Honest Dynasty Ltd
3.08%
Other
37.80%
Shareholder Types
Shareholders
Proportion
Corporation
62.20%
Investment Advisor
0.56%
Investment Advisor/Hedge Fund
0.15%
Hedge Fund
0.03%
Other
37.06%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
11
105.51K
0.14%
--
2025Q4
21
562.87K
0.74%
+457.95K
2025Q3
5
148.54K
0.20%
+138.11K
2025Q2
7
47.29M
62.20%
+47.29M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perfect Minds Co Ltd
25.35M
33.34%
+25.35M
--
Jun 17, 2025
Laxton Investments Company Ltd
7.63M
10.04%
+7.63M
--
Jun 17, 2025
Linkage Gladden Enterprise Ltd
6.86M
9.03%
+6.86M
--
Jun 17, 2025
Peak Valley International Co., Ltd.
5.10M
6.71%
+5.10M
--
Jun 17, 2025
Honest Dynasty Ltd
2.34M
3.08%
+2.34M
--
Jun 17, 2025
UBS Financial Services, Inc.
537.00
0%
+537.00
--
Sep 30, 2025
Geode Capital Management, L.L.C.
53.84K
0.07%
+43.41K
+416.29%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
